Download presentation
Presentation is loading. Please wait.
Published bySilke Morgenstern Modified over 5 years ago
1
Fig. 3. SUS treatment reduces different Aβ species.
SUS treatment reduces different Aβ species. (A to D) Western blotting of extracellular-enriched (A) and Triton-soluble (B) fractions of the brains of the first cohort of APP23 mice with 6E10 and 4G8 anti-Aβ antibodies revealed a reduction in distinct Aβ species in both fractions in SUS-treated compared to sham-treated mice. These data are quantified in (C) and (D), respectively. The Western blots show significant reductions of HMW species, the 56-kD oligomeric Aβ*56 (*56) and trimeric Aβ (3-mer)/CTFβ, in the extracellular-enriched fraction and of *56 and 3-mer/CTFβ in the Triton-soluble fraction (unpaired t tests, P < 0.05). GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used for normalization. MWM, molecular weight marker. (E) ELISA for Aβ42 in the Triton-soluble fraction revealed a significant reduction in SUS-treated compared to sham-treated mouse brains (unpaired t test, P < 0.05; n = 10 per group). Gerhard Leinenga and Jürgen Götz Sci Transl Med 2015;7:278ra33 Copyright © 2015, American Association for the Advancement of Science
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.